Edition:
United States

AcelRx Pharmaceuticals Inc (ACRX.OQ)

ACRX.OQ on NASDAQ Stock Exchange Global Market

3.15USD
21 Jul 2017
Change (% chg)

$0.05 (+1.61%)
Prev Close
$3.10
Open
$3.15
Day's High
$3.22
Day's Low
$3.08
Volume
126,319
Avg. Vol
92,177
52-wk High
$4.06
52-wk Low
$1.95

Select another date:

Wed, Jul 19 2017

BRIEF-Acelrx Pharmaceuticals appoints Raffi Asadorian CFO

* Acelrx Pharmaceuticals appoints Raffi Asadorian as chief financial officer

BRIEF-Acelrx Pharmaceuticals updates on notification from U.S. FDA

* U.S. FDA notified co that it no longer plans to hold an advisory committee meeting in connection with its review of NDA for Dsuvia

BRIEF-Acelrx Pharmaceuticals files for mixed shelf of up to $150 mln

* Acelrx Pharmaceuticals Inc files for mixed shelf of up to $150.0 million - sec filing Source text - http://bit.ly/2ruEt7F Further company coverage:

BRIEF-Acelrx Pharmaceuticals CFO Timothy Morris resigns

* Acelrx Pharmaceuticals - on June 2, CFO Timothy E. Morris notified co of his resignation from all positions with co effective immediately - SEC filing

BRIEF-AcelRx Pharmaceuticals reports Q1 total revenue $3.1 million

* AcelRx Pharmaceuticals reports first quarter 2017 financial results and provides corporate update

BRIEF-AcelRx Pharma says DSUVIA resulted in 3-point reduction in pain intensity within 60 minutes of administration

* AcelRx Pharmaceuticals presenting comprehensive DSUVIA clinical trial results at ASRA's annual regional anesthesiology and acute pain medicine meeting

BRIEF-European Medicines Agency begins evaluation of marketing application for sublingual Sufentanil

* European Medicines Agency begins evaluation of marketing application for sublingual Sufentanil 30 mcg tablet (ARX-04) for moderate-to-severe acute pain

BRIEF-Acelrx Pharmaceuticals Q4 loss per share $0.21

* Acelrx Pharmaceuticals reports fourth quarter and year end 2016 financial results

BRIEF-Acelrx says U.S. app to market painkiller Dsuvia accepted by FDA

* Acelrx pharmaceuticals' new drug application for dsuvia accepted for filing with pdufa date of october 12, 2017

BRIEF-Acelrx Pharmaceuticals appoints Vincent Angotti as CEO

* Acelrx Pharmaceuticals appoints Vincent J. Angotti chief executive officer

Select another date: